Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Humira Pen Psor-Uveits-Adol Hs(Adalimumab)

Medicare prescription drug cost, prescriptions and prescribers, 2024

$4.0M

Medicare cost, 2023

Medicare drug plans spent on Humira Pen Psor-Uveits-Adol Hs (adalimumab) in 2024, for prescriptions and refills. Spending fell 59% from 2022 to 2023.

Medicare cost, 2023

$4.0M

-59.4% from 2022

Prescriptions

282

$14,022.92 per claim

Patients

141

141 prescribers

Total spending

-

All plans

Questions and answers

How much does Medicare spend on Humira Pen Psor-Uveits-Adol Hs?

Medicare prescription drug plans paid $4.0M for Humira Pen Psor-Uveits-Adol Hs in 2023, for 282 prescriptions and refills to 141 patients (down 59.4% from 2022). The average cost per claim was $14,022.92.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022309750316$9.7M
2023141282141$4.0M

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube